ABVX shareholder Sofinnova Crossover I SLP has filed a notice of proposed sale under Rule 144 covering 1,000,000 ADS, to be sold through Leerink Partners on the NASDAQ. The filing lists an aggregate market value of 133700000.00 for these shares and an approximate sale date of 01/08/2026.
The ADS were originally acquired in a private placement from the issuer on 07/11/2019, with cash payment completed on 07/15/2019. The filing also notes that securities of the same issuer were sold in the prior three months: 590,877 ADS on 10/28/2025 for gross proceeds of 55638897.00, and 609,123 ADS on 10/29/2025 for gross proceeds of 57261354.00. Shares outstanding are shown as 77,800,000 ADS, providing context for the size of the planned sale.
Abivax SA reported significantly higher losses for the three and nine months ended September 30, 2025 as it advanced its lead drug obefazimod in inflammatory bowel disease.
For the third quarter of 2025, total operating income was €2.0 million versus €1.3 million a year earlier, but operating loss widened to €80.7 million from €50.2 million, mainly due to research and development expenses rising to €55.4 million and general and administrative costs to €25.5 million. Financial loss jumped to €72.6 million from €5.0 million, driven by fair‑value increases on convertible notes and Kreos/Claret warrants, foreign‑exchange losses and royalty certificate expenses.
Net loss reached €153.4 million for the quarter versus €55.2 million, and €254.1 million for the nine months versus €136.9 million. A sharp rise in employer taxes and social contributions on stock‑based compensation, linked to the higher share price, added about €29.6 million to third‑quarter operating costs. The company remains a clinical‑stage biotech: obefazimod delivered positive Phase 3 induction results in ulcerative colitis in July 2025, with 44‑week maintenance data expected in the second quarter of 2026, while Phase 2b Crohn’s disease trials and preclinical combination studies continue.
Venrock-affiliated funds filed Amendment No. 2 to Schedule 13G reporting a passive stake in Abivax SA (ABVX). The group reported beneficial ownership of 576,729 ordinary shares in the form of ADSs, representing 0.8% of the class as of September 30, 2025.
The holdings comprise 151,622 ADSs by VHCP III, 15,167 ADSs by VHCP Co-Investment III, and 409,940 ADSs by VHCP EG. Each ADS represents one ordinary share. The percentage was calculated against 73,574,749 ordinary shares outstanding as of July 28, 2025, per the issuer’s prospectus supplement. The reporting persons disclose shared voting and dispositive power over 576,729 shares and no sole power. They certified the securities were not acquired to change or influence control.
Abivax SA (ABVX): Schedule 13G/A filed reporting passive ownership by TCG Crossover affiliates and Chen Yu. The filing lists 7,111,596 Abivax ADSs beneficially owned by Chen Yu, equal to 9.1% of the ordinary shares. TCG Crossover Fund I holds 6,456,596 ADSs (8.3%), and TCG Crossover Fund II holds 655,000 ADSs (0.8%).
Each ADS represents one ordinary share. Percentages are based on 77,830,067 ordinary shares outstanding as of September 30, 2025. The reporting persons disclaim group status and certify the securities were not acquired to change or influence control.
Abivax SA (ABVX) — Schedule 13D/A Amendment No. 3: Sofinnova Crossover I SLP and affiliated reporting persons updated their ownership and disclosed recent open‑market sales of American Depositary Shares. As of September 30, 2025, they report holding 4,334,739 Ordinary Shares, representing approximately 5.6% of shares outstanding, and 8,399,478 voting rights, representing approximately 9.4% of voting rights. The base figures cited are 77,830,067 Ordinary Shares and 89,189,666 voting rights outstanding as of September 30, 2025.
The filing lists sales completed in multiple transactions: on October 28, 2025, 522,948 ADSs at a weighted average price of $94.00 per share and 67,929 ADSs at a weighted average price of $95.42; on October 29, 2025, 606,293 ADSs at a weighted average price of $94.00 and 2,830 ADSs at a weighted average price of $95.34. The reporting persons state the shares were acquired for investment purposes and reserve the right to buy or sell as permitted by law.
ABVX: A stockholder filed a Form 144 to sell up to 1,200,000 ADS, with an aggregate market value of $111,300,000. The proposed sale is listed for approximately 10/28/2025 through Leerink Partners on the NASDAQ.
The securities were acquired in the IPO on 10/20/2023, with 1,200,000 ADS purchased from the issuer and paid in cash on 10/24/2023. Shares outstanding were 77,800,000; this is a baseline figure, not the amount being offered.